Aldeyra Therapeutics (ALDX) Cash from Financing Activities (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Cash from Financing Activities of $71140.0 for Q1 2026, down 41.08% on a QoQ basis from $120746.0 in Q3 2025, and down 92.91% year-over-year from $1.0 million in Q1 2025.
Aldeyra Therapeutics (ALDX) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $71140.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 92.91% year-over-year to $71140.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $191886.0 (down 76.4% YoY) and the FY2025 annual result came in at $1.1 million, up 755.43% from the prior year.
- Cash from Financing Activities was $71140.0 for Q1 2026 at Aldeyra Therapeutics, down from $120746.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $1.2 million in Q3 2022 and bottomed at -$1.0 million in Q4 2023.
- A 5-year average of $81095.5 and a median of $20757.5 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities plunged 126.38% — and 2025, when it soared 5412.67%.
- Aldeyra Therapeutics' Cash from Financing Activities stood at $1.2 million in 2022, then plunged by 184.59% to -$1.0 million in 2023, then soared by 100.77% to $7779.0 in 2024, then soared by 1452.2% to $120746.0 in 2025, then tumbled by 41.08% to $71140.0 in 2026.
- Business Quant data shows ALDX's Cash from Financing Activities at $71140.0 in Q1 2026, $120746.0 in Q3 2025, and $1.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 238.74 Mn |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - | 71,140.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 71,140.00 |
| Mar 31, 2026 | 71,140.00 |
| Sep 30, 2025 | 120,746.00 |
| Sep 30, 2025 | 120,746.00 |
| Mar 31, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 7,779.00 |
| Dec 31, 2024 | 7,779.00 |
| Sep 30, 2024 | -197,392.00 |
| Sep 30, 2024 | -197,392.00 |
| Mar 31, 2024 | 18,191.00 |
| Mar 31, 2024 | 18,191.00 |
| Dec 31, 2023 | -1.01 Mn |
| Dec 31, 2023 | -1.01 Mn |
| Sep 30, 2023 | -315,759.00 |
| Sep 30, 2023 | -315,759.00 |
| Jun 30, 2023 | 5,292.00 |
| Jun 30, 2023 | 5,292.00 |
| Mar 31, 2023 | 52,559.00 |
| Mar 31, 2023 | 52,559.00 |